Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD

References

• Lee ES, Park BR, Kim JS, et al. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr Med Res Opin 2013;29:141–147
   PubMed Web of Science ®Google Scholar
• Madore F, White CT, Foley RN, et al. Clinical practice guidelines for assessment and management of iron deficiency. Kidney Int Suppl. 2008;74:S7–S11
   Google Scholar
• Gasche C, Evstatiev R, Haas T, et al. Diagnosis and treatment of iron deficiency and anaemia in inflammatory bowel diseases. Consensus of the Austrian IBD Working Party. Z Gastroenterol Mai 2011;49:627–632
   PubMedGoogle Scholar
• Breymann C, Bian X-M, Blanco-Capito LR, et al. Expert recommendations for the diagnosis and treatment of iron-deficiency anemia during pregnancy and the postpartum period in the Asia-Pacific region. J Perinat Med März 2011;39:113–121
   PubMed Web of Science ®Google Scholar
• Gomollón F, Gisbert JP. Intravenous iron in inflammatory bowel diseases. Curr Opin Gastroenterol 2013;29:201–207
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Geisser P. Use of intravenous iron supplementation in chronic kidney disease: an update. Iran J Kidney Dis 2013;7:9–22
   PubMed Web of Science ®Google Scholar
• Toblli J, Cao G, Oliveri L, Angerosa M. Differences between original intravenous iron sucrose and iron sucrose similar preparations. Arzneimittelforschung 2011;59:176–190
   Web of Science ®Google Scholar
• Rottembourg J, Kadri A, Leonard E, et al. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant 2011;26:3262–3267
   PubMed Web of Science ®Google Scholar
• Schellekens H, Klinger E, Mühlebach S, et al. The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol 2011;59:176–183
   PubMed Web of Science ®Google Scholar
• Toblli JE, Cao G, Oliveri L, Angerosa M. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm Allergy Drug Targets 2012;11:66–78
   PubMedGoogle Scholar
• Stein J, Dignass A, Chow KU. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr Med Res Opin 2012;28:241–243
   PubMed Web of Science ®Google Scholar
• Toblli JE, Cao G, Olivieri L, Angerosa M. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrol Dial Transplant 2010;25:3631–3640
   PubMed Web of Science ®Google Scholar
• Toblli JE, Cao G, Oliveri L. Differences between the original iron sucrose complex Venofer® and the iron sucrose similar Generis®, and potential implications. Port J Nephrol Hypert 2009;23:53–63
   Google Scholar
• Bailie GR, Schuler C, Leggett RE, et al. Oxidative effect of several intravenous iron complexes in the rat. Biometals 2013;26:473–478
   PubMed Web of Science ®Google Scholar
• Martin-Malo A, Merino A, Carracedo J, et al. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant 2012;27:2465–2471
   PubMed Web of Science ®Google Scholar
• Meier T, Schropp P, Pater C, et al. Physicochemical and toxicological characterization of a new generic iron sucrose preparation. Arzneimittelforschung 2011;61:112–119
   PubMed Web of Science ®Google Scholar
• Elford P, Bouchard J, Jaillet L, et al. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose. J Pharmacol Toxicol Methods 2013;68:374--383
   PubMed Web of Science ®Google Scholar
• Schaller G, Scheiber-Mojdehkar B, Wolzt M, et al. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Kidney Int 2005;68:2814–2822
   PubMed Web of Science ®Google Scholar
• Danielson BG, Salmonson T, Derendorf H, Geisser P. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 1996;46:615–621
   PubMed Web of Science ®Google Scholar
• Fish WW. Rapid colorimetric micromethod for the quantitation of complexed iron in biological samples. Meth Enzymol 1988;158:357–364
   PubMed Web of Science ®Google Scholar
• Sturm B, Goldenberg H, Scheiber-Mojdehkar B. Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations. Eur J Biochem 2003;270:3731–3738
   PubMedGoogle Scholar
• Breuer W, Cabantchik ZI. A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem 2001;299:194–202
   PubMed Web of Science ®Google Scholar
• Esposito BP, Breuer W, Sirankapracha P, et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003;102:2670–2677
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Meth Enzymol 1990;186:1–85
   PubMed Web of Science ®Google Scholar
• Rothman RJ, Serroni A, Farber JL. Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury. Mol Pharmacol 1992;42:703–710
   PubMed Web of Science ®Google Scholar
• Stäubli A, Boelsterli UA. The labile iron pool in hepatocytes: prooxidant-induced increase in free iron precedes oxidative cell injury. Am J Physiol Gastrointest Liver Physiol 1998;274:G1031–G1037
   Web of Science ®Google Scholar
• Breuer W, Greenberg E, Cabantchik ZI. Newly delivered transferrin iron and oxidative cell injury. FEBS Lett 1997;403:213–219
   PubMed Web of Science ®Google Scholar
• Picard V, Renaudie F, Porcher C, et al. Overexpression of the ferritin H subunit in cultured erythroid cells changes the intracellular iron distribution. Blood 1996;87:2057–2064
   PubMed Web of Science ®Google Scholar
• Lipiński P, Drapier J-C, Oliveira L, et al. Intracellular iron status as a hallmark of mammalian cell susceptibility to oxidative stress: a study of L5178Y mouse lymphoma cell lines differentially sensitive to H2O2. Blood 2000;95:2960–2966
   PubMed Web of Science ®Google Scholar
• Pierre JL, Fontecave M, Crichton RR. Chemistry for an essential biological process: the reduction of ferric iron. Biometals 2002;15:341–346
   PubMed Web of Science ®Google Scholar
• Crichton R, Danielson B, Geisser P. Iron therapy with special emphasis on intravenous administration. Bremen (Germany): UNI-MED; 2008:57–88
   Google Scholar
• Sturm B, Laggner H, Ternes N, et al. Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable iron. Kidney Int 2005;67:1161–1170
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JM. Free radicals in biology and medicine. 3rd ed. Oxford: Oxford Science Publications; 1999:191–198
   Google Scholar
• Stein J, Dignass A, Chow KU. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr Med Res Opin 2012;28:241–243
   PubMed Web of Science ®Google Scholar
• Scheiber-Mojdehkar B, Sturm B, Plank L, et al. Influence of parenteral iron preparations on non-transferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells. Biochem Pharmacol 2003;65:1973–1978
   PubMed Web of Science ®Google Scholar
• Ternes N, Scheiber-Mojdehkar B, Landgraf G, et al. Iron availability and complex stability of iron hydroxyethyl starch and iron dextran a comparative in vitro study with liver cells and macrophages. Nephrol Dial Transplant 2007;22:2824–2830
   PubMed Web of Science ®Google Scholar
• Sturm B, Steinkellner H, Ternes N, et al. In vitro study on the effects of iron sucrose, ferric gluconate and iron dextran on redox-active iron and oxidative stress. Arzneimittelforschung 2010;60:459–465
   PubMed Web of Science ®Google Scholar
• Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol 2012;89:87–93
   PubMed Web of Science ®Google Scholar
• Kakhlon O, Cabantchik ZI. The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic Biol Med 2002;33:1037–1046
   PubMed Web of Science ®Google Scholar